Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

368 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis.
Alchalby H, Badbaran A, Zabelina T, Kobbe G, Hahn J, Wolff D, Bornhäuser M, Thiede C, Baurmann H, Bethge W, Hildebrandt Y, Bacher U, Fehse B, Zander AR, Kröger N. Alchalby H, et al. Among authors: thiede c. Blood. 2010 Nov 4;116(18):3572-81. doi: 10.1182/blood-2009-12-260588. Epub 2010 May 20. Blood. 2010. PMID: 20489052 Free article.
Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells.
Bornhauser M, Storer B, Slattery JT, Appelbaum FR, Deeg HJ, Hansen J, Martin PJ, McDonald GB, Nichols WG, Radich J, Woolfrey A, Jenke A, Schleyer E, Thiede C, Ehninger G, Anasetti C. Bornhauser M, et al. Among authors: thiede c. Blood. 2003 Aug 1;102(3):820-6. doi: 10.1182/blood-2002-11-3567. Epub 2003 Apr 3. Blood. 2003. PMID: 12676781 Free article. Clinical Trial.
Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML.
Bornhäuser M, Illmer T, Schaich M, Soucek S, Ehninger G, Thiede C; AML SHG 96 study group. Bornhäuser M, et al. Among authors: thiede c. Blood. 2007 Mar 1;109(5):2264-5; author reply 2265. doi: 10.1182/blood-2006-09-047225. Blood. 2007. PMID: 17312001 Free article. No abstract available.
Gemtuzumab ozogamicin as part of reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in patients with relapsed acute myeloid leukemia.
Bornhäuser M, Illmer T, Oelschlaegel U, Schetelig J, Ordemann R, Schaich M, Hänel M, Schuler U, Thiede C, Kiani A, Platzbecker U, Ehninger G. Bornhäuser M, et al. Among authors: thiede c. Clin Cancer Res. 2008 Sep 1;14(17):5585-93. doi: 10.1158/1078-0432.CCR-08-0894. Clin Cancer Res. 2008. PMID: 18765552 Clinical Trial.
368 results